Zobrazeno 1 - 10
of 671
pro vyhledávání: '"Bruce D. Cheson"'
Autor:
Sriram Balasubramanian, Brendan Hodkinson, Stephen J. Schuster, Nathan H. Fowler, Judith Trotman, Georg Hess, Bruce D. Cheson, Michael Schaffer, Steven Sun, Sanjay Deshpande, Jessica Vermeulen, Gilles Salles, Ajay K. Gopal
Publikováno v:
Cancer Medicine, Vol 11, Iss 1, Pp 61-73 (2022)
Abstract Background The single‐arm DAWN trial (NCT01779791) of ibrutinib monotherapy in patients with relapsed/refractory follicular lymphoma (FL) showed an overall response rate (ORR) of 20.9% and a median response duration of 19.4 months. This bi
Externí odkaz:
https://doaj.org/article/8e668f1ebce046fb90165c45e83463d9
Publikováno v:
Blood Cancer Journal, Vol 11, Iss 4, Pp 1-10 (2021)
Abstract Newer, more effective and non-cytotoxic therapies are an unmet need for patients with diffuse large B-cell lymphoma (DLBCL) and other B-cell malignancies. Recently approved agents include polatuzumab with bendamustine and rituximab, selinexo
Externí odkaz:
https://doaj.org/article/15deeebcca0044969732fd32c9b87a96
Autor:
Kerry A. Rogers, Philip A. Thompson, John N. Allan, Morton Coleman, Jeff P. Sharman, Bruce D. Cheson, Daniel Jones, Raquel Izumi, Melanie M. Frigault, Cheng Quah, Rakesh K. Raman, Priti Patel, Min Hui Wang, Thomas J. Kipps
Publikováno v:
Haematologica, Vol 106, Iss 9 (2021)
B-cell receptor signalling inhibition by targeting Bruton tyrosine kinase (BTK) is effective in treating chronic lymphocytic leukemia (CLL). The BTK inhibitor ibrutinib may be intolerable for some patients. Acalabrutinib is a more selective BTK inhib
Externí odkaz:
https://doaj.org/article/1f8e5a0d250d49f8bc29eb2cbf686fb6
Autor:
Toby A. Eyre, Nicole Lamanna, Lindsey E. Roeker, Chaitra S. Ujjani, Brian T. Hill, Paul M. Barr, Erick Lansigan, Bruce D. Cheson, Maryam Yazdy, John N. Allan, Joanna Rhodes, Stephen J. Schuster, Chadi Nabhan, Alan Skarbnik, Lori Leslie, Prioty Islam, Katherine Whitaker, Catherine C. Coombs, Hande H. Tuncer, John M. Pagel, Ryan Jacobs, Allison M. Winter, Neil Bailey, Andrea Sitlinger, Anna H. Schuh, George Follows, Christopher P. Fox, Danielle M. Brander, Mazyar Shadman, Anthony R. Mato
Publikováno v:
Haematologica, Vol 106, Iss 1 (2020)
Externí odkaz:
https://doaj.org/article/ad08843e37b24e96ad4960bf18e8f92a
Autor:
Paolo Ghia, Steven E. Coutre, Bruce D. Cheson, Jacqueline C. Barrientos, Peter Hillmen, Andrew R. Pettitt, Andrew D. Zelenetz, Sanatan Shreay, Michael Hallek, Richard R. Furman
Publikováno v:
Haematologica, Vol 105, Iss 10 (2020)
Externí odkaz:
https://doaj.org/article/9855e6dd543348bdb5a1554b9616880d
Autor:
Anthony R. Mato, William G. Wierda, Matthew S. Davids, Bruce D. Cheson, Steven E. Coutre, Michael Choi, Richard R. Furman, Leonard Heffner, Paul M. Barr, Herbert Eradat, Sharanya M. Ford, Lang Zhou, Maria Verdugo, Rod A. Humerickhouse, Jalaja Potluri, John C. Byrd
Publikováno v:
Haematologica, Vol 104, Iss 11 (2019)
The utility of positron emission tomography-computed tomography (PET-CT) in distinguishing Richter’s transformation versus chronic lymphocytic leukemia (CLL) progression after ibrutinib and/or idelalisib was assessed in a post hoc analysis of a pha
Externí odkaz:
https://doaj.org/article/2eb9743dadf8446b8ea8d2185f71d8bf
Autor:
Chaitra Ujjani, Hongkun Wang, Alan Skarbnik, Neel Trivedi, Pari Ramzi, Nadia Khan, Bruce D. Cheson
Publikováno v:
Blood Advances, Vol 2, Iss 7, Pp 762-768 (2018)
Abstract: Attempts to improve upon the activity of ibrutinib in chronic lymphocytic leukemia (CLL) include the addition of targeted therapies. The combination of lenalidomide and rituximab demonstrated an overall response rate (ORR) of 66% with a com
Externí odkaz:
https://doaj.org/article/45baaa80a4f74cdcb6f0751ed011b580
Autor:
Anthony R. Mato, Meghan Thompson, John N. Allan, Danielle M. Brander, John M. Pagel, Chaitra S. Ujjani, Brian T. Hill, Nicole Lamanna, Frederick Lansigan, Ryan Jacobs, Mazyar Shadman, Alan P. Skarbnik, Jeffrey J. Pu, Paul M. Barr, Alison R. Sehgal, Bruce D. Cheson, Clive S. Zent, Hande H. Tuncer, Stephen J. Schuster, Peter V. Pickens, Nirav N. Shah, Andre Goy, Allison M. Winter, Christine Garcia, Kaitlin Kennard, Krista Isaac, Colleen Dorsey, Lisa M. Gashonia, Arun K. Singavi, Lindsey E. Roeker, Andrew Zelenetz, Annalynn Williams, Christina Howlett, Hanna Weissbrot, Naveed Ali, Sirin Khajavian, Andrea Sitlinger, Eve Tranchito, Joanna Rhodes, Joshua Felsenfeld, Neil Bailey, Bhavisha Patel, Timothy F. Burns, Melissa Yacur, Mansi Malhotra, Jakub Svoboda, Richard R. Furman, Chadi Nabhan
Publikováno v:
Haematologica, Vol 103, Iss 9 (2018)
Venetoclax is a BCL2 inhibitor approved for 17p-deleted relapsed/refractory chronic lymphocytic leukemia with activity following kinase inhibitors. We conducted a multicenter retrospective cohort analysis of patients with chronic lymphocytic leukemia
Externí odkaz:
https://doaj.org/article/cf0cc2d2d3144e71a74d686f011301aa
Autor:
Anthony R. Mato, Chadhi Nabhan, Meghan C. Thompson, Nicole Lamanna, Danielle M. Brander, Brian Hill, Christina Howlett, Alan Skarbnik, Bruce D. Cheson, Clive Zent, Jeffrey Pu, Pavel Kiselev, Andre Goy, David Claxton, Krista Isaac, Kaitlin H. Kennard, Colleen Timlin, Daniel Landsburg, Allison Winter, Sunita D. Nasta, Spencer H. Bachow, Stephen J. Schuster, Colleen Dorsey, Jakub Svoboda, Paul Barr, Chaitra S. Ujjani
Publikováno v:
Haematologica, Vol 103, Iss 5 (2018)
Clinical trials that led to ibrutinib’s approval for the treatment of chronic lymphocytic leukemia showed that its side effects differ from those of traditional chemotherapy. Reasons for discontinuation in clinical practice have not been adequately
Externí odkaz:
https://doaj.org/article/a606b178c28248cb9a40c8b3853c496c
Autor:
Lale eKostakoglu, Bruce D. Cheson
Publikováno v:
Frontiers in Oncology, Vol 3 (2013)
Lymphomas are heterogeneous but potentially curable group of neoplasms. Treatment of lymphomas has rapidly evolved overtime with significant improvement in the cure rate and reductions in treatment-related toxicities. Despite excellent results, treat
Externí odkaz:
https://doaj.org/article/3428bc3e673a4100bed6544a831a2f4c